MedTrace Logo

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

NCT00973323 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-12-30

No results posted yet for this study

Summary

This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).

Conditions

Interventions

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

2.5mg bid

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

5mg bid

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

10mg bid

DRUG

Warfarin

Dose-adjusted warfarin based on target INR values

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973323 on ClinicalTrials.gov